SteelPeak Wealth LLC Boosts Stock Holdings in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

SteelPeak Wealth LLC increased its position in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 9.8% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,400 shares of the company’s stock after purchasing an additional 1,550 shares during the period. SteelPeak Wealth LLC’s holdings in Day One Biopharmaceuticals were worth $242,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in DAWN. Mirae Asset Global Investments Co. Ltd. grew its position in Day One Biopharmaceuticals by 38.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after buying an additional 1,002 shares during the period. SG Americas Securities LLC acquired a new position in Day One Biopharmaceuticals during the second quarter worth about $113,000. Point72 DIFC Ltd acquired a new position in Day One Biopharmaceuticals during the second quarter worth about $124,000. Hsbc Holdings PLC acquired a new position in Day One Biopharmaceuticals during the second quarter worth about $163,000. Finally, Bayesian Capital Management LP acquired a new position in Day One Biopharmaceuticals during the first quarter worth about $221,000. 87.95% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total transaction of $426,600.00. Following the transaction, the insider now owns 1,097,535 shares of the company’s stock, valued at $15,606,947.70. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $14.22, for a total transaction of $426,600.00. Following the transaction, the insider now owns 1,097,535 shares of the company’s stock, valued at $15,606,947.70. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Samuel C. Blackman sold 2,232 shares of the stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total transaction of $31,248.00. Following the transaction, the insider now directly owns 1,127,535 shares in the company, valued at approximately $15,785,490. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 48,748 shares of company stock valued at $689,072 over the last quarter. Company insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Stock Performance

Shares of NASDAQ DAWN opened at $14.65 on Friday. Day One Biopharmaceuticals, Inc. has a 1 year low of $10.90 and a 1 year high of $18.07. The firm’s 50 day moving average price is $14.19 and its 200 day moving average price is $14.39. The firm has a market cap of $1.29 billion, a P/E ratio of -14.22 and a beta of -1.51.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings results on Wednesday, October 30th. The company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.58. The company had revenue of $93.76 million for the quarter, compared to analysts’ expectations of $15.05 million. During the same period in the prior year, the business earned ($0.54) EPS. As a group, equities analysts predict that Day One Biopharmaceuticals, Inc. will post -1.65 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently commented on DAWN. Needham & Company LLC reiterated a “buy” rating and issued a $33.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday. Piper Sandler reiterated an “overweight” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Thursday. Bank of America upgraded shares of Day One Biopharmaceuticals from an “underperform” rating to a “buy” rating and increased their price target for the company from $11.00 to $24.00 in a research report on Thursday, August 1st. Finally, JPMorgan Chase & Co. lowered their price target on shares of Day One Biopharmaceuticals from $38.00 to $36.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Day One Biopharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $35.71.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.